On this page
N-acetylglutamate synthase deficiency
This condition is caused by a problem in the urea cycle, a process that removes harmful ammonia from the body. Without a properly working urea cycle, ammonia can build up, leading to serious health issues, particularly in newborns and young children.
Available at Jeen Health
Clinical tests that include this
Overview
N-acetylglutamate synthase (NAGS) deficiency is a very rare inherited metabolic disorder. It affects a vital process called the urea cycle, which is responsible for converting excess nitrogen, a waste product, into urea for excretion from the body. When the NAGS enzyme is deficient, this critical step in the urea cycle cannot function correctly, leading to a build-up of ammonia in the bloodstream [PMID:31720165].
Ammonia is toxic to the central nervous system, and high levels can cause significant damage, especially to the brain. The severity of symptoms can vary, but in its most severe form, NAGS deficiency can lead to life-threatening complications if not diagnosed and treated promptly. It is often identified in the newborn period due to its acute presentation.
Symptoms & clinical features
Symptoms of NAGS deficiency often appear very early in life, typically within the first few days after birth. These can be non-specific and may include poor feeding, lethargy, vomiting, and irritability. As ammonia levels rise, more severe neurological symptoms may develop, such as hypotonia (poor muscle tone), seizures, and coma [PMID:31720165].
In some cases, individuals may experience a later onset of symptoms, though this is less common. These might include episodes of confusion, headaches, behavioural changes, or developmental delay. The presentation of symptoms is directly related to the accumulation of ammonia, making timely diagnosis and management crucial to prevent neurological damage.
Video: Genetics 101
Affected organs
The primary organs affected by N-acetylglutamate synthase deficiency are the brain and liver. The liver is where the urea cycle primarily takes place, and a defect in this process leads to the accumulation of ammonia.
The brain is particularly vulnerable to the toxic effects of high ammonia levels, known as hyperammonaemia. This can result in cerebral oedema (brain swelling) and irreversible neurological damage if not treated quickly and effectively. Other organ systems may be indirectly affected due to the overall metabolic stress on the body.
Risks & severity
NAGS deficiency is considered a severe condition, particularly in neonates, where it can be life-threatening if untreated. The severity is largely determined by the degree of enzyme deficiency and how quickly hyperammonaemia develops and is addressed. Early diagnosis and intervention are critical for improving outcomes.
The lifetime risks are significant due to the potential for recurrent episodes of hyperammonaemia, which can lead to progressive neurological impairment, developmental delay, and intellectual disability. With effective management, including dietary changes and medication, some individuals can achieve better outcomes, but the condition still requires lifelong vigilance [PMID:31720165]. The exact prevalence of NAGS deficiency is not well established due to its rarity.
Genetic causes
N-acetylglutamate synthase deficiency is caused by pathogenic variants (sometimes called mutations) in the NAGS gene. This gene provides instructions for making the N-acetylglutamate synthase enzyme. This enzyme plays a crucial role in the urea cycle by producing N-acetylglutamate, which is an essential activator for carbamoyl phosphate synthetase I (CPSI), another key enzyme in the urea cycle [PMID:20301479].
When the NAGS enzyme is not working correctly due to a pathogenic variant in the NAGS gene, N-acetylglutamate cannot be produced efficiently. This means CPSI is not activated, and the urea cycle effectively stalls. As a result, ammonia, which is normally converted into urea, builds up to toxic levels in the blood. The type and location of the genetic change within the NAGS gene can influence how severely the enzyme's function is impaired.
- NAGS N-acetylglutamate synthaseThe NAGS gene provides instructions for creating N-acetylglutamate synthase, an enzyme critical for the urea cycle, which processes excess nitrogen to prevent toxic ammonia accumulation in the body.
Inheritance pattern
N-acetylglutamate synthase deficiency is inherited in an autosomal recessive pattern. This means that an individual must inherit two altered copies of the NAGS gene - one from each parent - to develop the condition.
People who carry only one altered copy of the NAGS gene are called carriers. Carriers typically do not show symptoms of NAGS deficiency because their one working copy of the gene is usually sufficient to produce enough of the NAGS enzyme. When two carriers have a child together, there is a 25% chance with each pregnancy that the child will inherit two altered copies and develop the condition, a 50% chance the child will be a carrier, and a 25% chance the child will inherit two working copies and not be affected or a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of NAGS deficiency typically begins with clinical suspicion in an infant presenting with unexplained lethargy, poor feeding, or seizures, particularly if accompanied by elevated blood ammonia levels. Initial biochemical tests often reveal hyperammonaemia and characteristic changes in amino acid levels. Exclusion of other causes of hyperammonaemia is important.
Definitive diagnosis is confirmed through genetic testing, which identifies pathogenic variants in the NAGS gene. Genetic testing for NAGS deficiency is covered by the NHS Genomic Medicine Service under specific R-codes, following referral from a specialist clinician. Referral to a clinical genetics service is essential for accurate diagnosis and genetic counselling.
Management & lifestyle
Management of NAGS deficiency focuses on reducing ammonia levels and preventing neurological damage. In acute hyperammonaemic crises, emergency treatment involves measures to rapidly lower ammonia, which may include intravenous medications that help remove ammonia from the body, and in severe cases, dialysis. Dietary management is also critical, typically involving a low-protein diet to reduce the amount of nitrogen the body needs to process.
Long-term management often includes oral medication, such as N-carbamylglutamate (a synthetic analogue of N-acetylglutamate), which directly activates CPSI and restores function to the urea cycle. Regular monitoring of ammonia levels and growth is important. Management is typically guided by specialist metabolic teams within the NHS, often involving dietitians, paediatricians, and genetic specialists. Genetic counsellors can provide support and information regarding the genetic aspects of the condition and its implications for families.
UK care pathway
In the UK, individuals suspected of having an inherited metabolic disorder like NAGS deficiency would typically be referred through their GP or paediatrician to a specialist metabolic centre. Diagnosis often involves biochemical investigations followed by genetic testing, which is available through the NHS Genomic Medicine Service. Genetic testing for specific conditions like NAGS deficiency falls under particular R-codes within the national testing directory. Following diagnosis, care is managed by a multidisciplinary team, and genetic counselling is provided to discuss the inheritance pattern and implications for family planning.
Frequently asked questions
What happens if N-acetylglutamate synthase deficiency is not treated?
If left untreated, N-acetylglutamate synthase deficiency can lead to severe and life-threatening complications. The build-up of ammonia in the blood is toxic to the brain, causing swelling, seizures, coma, and potentially irreversible neurological damage or death. Early diagnosis and treatment are crucial to prevent these serious outcomes.
Can carriers of NAGS deficiency develop symptoms?
Individuals who are carriers for NAGS deficiency (meaning they have one altered copy of the NAGS gene) typically do not develop symptoms of the condition. They have enough of the functional NAGS enzyme from their other gene copy to prevent ammonia build-up. Carriers only face a risk of passing the altered gene to their children.
Is there a cure for N-acetylglutamate synthase deficiency?
There is currently no cure for N-acetylglutamate synthase deficiency. However, effective treatments are available to manage the condition and prevent complications. These treatments focus on reducing ammonia levels through diet modifications and specific medications, such as N-carbamylglutamate, which can help restore urea cycle function.
How common is N-acetylglutamate synthase deficiency?
N-acetylglutamate synthase deficiency is an extremely rare condition. Due to its rarity, the exact prevalence is not precisely known, but it is considered one of the less common types of urea cycle disorders.
What kind of doctors treat N-acetylglutamate synthase deficiency in the UK?
In the UK, NAGS deficiency is managed by specialist multidisciplinary teams, typically at a metabolic centre. This team often includes paediatricians, metabolic consultants, dietitians, and genetic counsellors. They work together to provide comprehensive care, including diagnosis, treatment, and long-term management.
References
- Kenneson A, Singh RH. Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature. Orphanet journal of rare diseases. 2020. PMID: 33036647
- Adam MP, Bick S, Mirzaa GM. Urea Cycle Disorders Overview. 1993. PMID: 20301396
- Ah Mew N, Caldovic L. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. The application of clinical genetics. 2011. PMID: 23776373
- Sonaimuthu P, Senkevitch E, Haskins N. Gene delivery corrects N-acetylglutamate synthase deficiency and enables insights in the physiological impact of L-arginine activation of N-acetylglutamate synthase. Scientific reports. 2021. PMID: 33574402
- Cavicchi C, Chilleri C, Fioravanti A. Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature. International journal of molecular sciences. 2018. PMID: 29364180
- Ah Mew N, Lichter-Konecki U. Current Treatment Modalities for Urea Cycle Disorders. Paediatric drugs. 2025. PMID: 40976841
- Selvanathan A, Demetriou K, Lynch M. N-acetylglutamate synthase deficiency with associated 3-methylglutaconic aciduria: A case report. JIMD reports. 2022. PMID: 36101823
- Häberle J. Carglumic acid for the treatment of N-acetylglutamate synthase deficiency and acute hyperammonemia. Expert review of endocrinology & metabolism. 2012. PMID: 30780843